scholarly journals Can oral iron tablets be replaced by the intravenous iron sucrose in antenatal period? A new thought.

2018 ◽  
Vol 7 (8) ◽  
pp. 3103
Author(s):  
Snehal S. Tate ◽  
Arti S. Shirsath ◽  
Neelesh S. Risbud
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anaemia ◽  
Intravenous Iron ◽  
Oral Iron ◽  
Iron Sucrose ◽  
Iron Therapy ◽  
Deficiency Anaemia ◽  
Significant Difference ◽  
Oral Group ◽  
Intravenous Iron Therapy

Background: Anaemia is the commonest medical disorder that contributes significantly to maternal morbidity and mortality, preterm delivery, intrauterine growth restriction. Pregnant women are particularly vulnerable to anaemia because they have dual iron requirements both for their growth and growth of foetus. A high proportion of women in both industrialized and developing countries become anaemic during pregnancy. Intravenous iron therapy is safe convenient and effective than oral iron therapy in prevention of iron deficiency anaemia when compliance is the problem. The aim of this study is to compare the efficacy, safety and acceptability of intravenous iron Vs oral iron in prevention of iron deficiency anaemia during pregnancy. The objective of the present research was to study the efficacy, safety and acceptability of oral iron (ferrous fumarate) versus intravenous iron (iron sucrose) for the prevention of iron deficiency anaemia during pregnancy.Methods: It was a prospective comparative case control study without blinding including 400 registered antenatal women in SKNMC and GH, Narhe, Pune. Results were based on collection and analysis of data from samples within study population.Results: There was no significant difference in mean haemoglobin rise between oral group and IV group but there is significant difference between mean ferritin levels between oral group and IV group. In IV group ferritin levels at 36 weeks were almost 1.8 times more than oral group. Acceptability and convenience of IV iron was significantly more than oral iron.Conclusions: Intravenous iron therapy in the form of three divided doses, one in each trimester can be safely used in the antenatal woman as an alternative to prophylactic iron tablets for prevention of iron deficiency anaemia especially in women who are non-compliant or does not tolerate oral iron tablets.

scholarly journals A study of efficacy of oral iron and intravenous iron sucrose in the treatment of moderate anemia in pregnancy

2019 ◽  
Vol 8 (6) ◽  
pp. 2221
Author(s):  
Saloni M. Prajapati ◽  
Meha K. Patel
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anaemia ◽  
Intravenous Iron ◽  
Oral Iron ◽  
Iron Sucrose ◽  
Iron Therapy ◽  
Deficiency Anemia ◽  
Deficiency Anaemia ◽  
Blood Indices ◽  
In Pregnancy

Background: Iron deficiency anaemia in pregnancy is a common medical problem throughout India with the burden of disease impacting on both mother and the newborn. It is also responsible for increased incidence of premature births, low birth weight babies and high perinatal mortality. Intravenous iron sucrose and oral iron therapy are the primary therapeutic modalities for management of iron deficiency anaemia during pregnancy, but its efficacy during pregnancy is still a matter of argument among healthcare personnel. Therefore the objective of this study is to compare the effect of oral iron and intravenous iron sucrose on hemoglobin and other blood indices among pregnant females with iron deficiency anemia.Methods: Randomized clinical trial was conducted among 400 females between 20 to 34 weeks gestation with iron deficiency anemia who were managed either with oral ferrous sulphate or intravenous iron sucrose therapy. Z test was used for statistical analysis for significance with 95% confidence interval. The hemoglobin and blood indices levels before and after initiating treatment in both groups were compared.Results: Intravenous and oral; both the treatments were associated with increment in hemoglobin but this rise was significantly more in the intravenous group than in oral. Comparing participants with low pretreatment hemoglobin among both groups, participants in the intravenous group were better benefited than oral due to respective treatment.Conclusions: Intravenous iron therapy is much effective in correcting iron deficiency anemia in pregnancy than oral iron therapy. It restores iron stores more promptly. Also intravenous iron is better tolerated compared to oral iron.

A Prospective Randomised Trial of Intravenous Iron Therapy Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Australian Women

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 3750-3750 ◽  
Author(s):  
Alhossain A. Khalafallah ◽  
Amanda Dennis ◽  
Joan Bates ◽  
Gerald Bates ◽  
Lauern Smith ◽  
...  
Keyword(s):  
Iron Deficiency ◽  
Pregnant Women ◽  
Serum Ferritin ◽  
Iron Deficiency Anaemia ◽  
Intravenous Iron ◽  
Oral Iron ◽  
Iron Therapy ◽  
Deficiency Anaemia ◽  
Iv Iron ◽  
Intravenous Iron Therapy

Abstract To date, limited data is available regarding prevalence of iron deficiency during pregnancy in Australia. There is little if any data currently available regarding comparative efficacy of IV iron versus oral iron therapy in pregnant women. In Australia the prevalence of iron deficiency anaemia (IDA) is approximately 5% in the general population with higher rates in pregnant women. At a single site, the Launceston General Hospital (LGH), we prospectively investigated 200 pregnant women between January and July 2007 with FBC and iron studies at the first or second antenatal visit. Among those, 40 women (20%) had iron deficiency anaemia, and were recruited to a prospective randomised trial to determine whether intravenous iron therapy (iron polymaltose) is superior to oral iron (ferrous sulphate) for the management of IDA associated with pregnancy. The patients’ median age was 28 years old (range; 19–40) with a median gestational age at recruitment of 27 weeks (range; 13–29) and a median body weight of 74 kg (range; 47–130). At recruitment median Hb was 106 g/L (range; 90–114, normal range; 120–160 g/L), while median serum ferritin was 11.5 μg/L and mean ferritin was 19 μg/L normal range; 30–460). After four weeks of treatment the Hb level increased by a mean of 6g/L on oral iron and by 10.5 g/L after IV iron. Mean/Median serum ferritin did not increase significantly in women on oral iron, but increased to a median of 96.5 μg/L and a mean of 224 μg/L in those received IV iron. Multi-variate analysis using general linear modelling for continuous variables showed a significant increase in serum ferritin after treatment with IV iron versus oral iron (p=0.017). There was no statistically significant difference in terms of Hb increment, patients’ parity, weight, and date of last pregnancy between groups. Analysis of quality of life questionnaires to assess patients’ well-being, ability to perform activities, and symptoms of anaemia showed improvement in both groups of patients with a trend to greater and faster improvement after IV iron. Both treatments were well tolerated without major side effects. The preliminary data indicate IDA is a common finding during pregnancy in the LGH population, and intravenous iron therapy appears a safe and effective treatment in this cohort of patients. This research received a grant from the Clifford Craig Medical Research Trust, Tasmania, Australia.

scholarly journals Evaluation of Intravenous Iron Therapy Response to Manage Anemia in Pregnancy

2018 ◽  
Vol 27 (1) ◽  
pp. 79-82
Author(s):  
Joysree Saha ◽  
Md Abdul Quader ◽  
Ferdousi Islam ◽  
Indrajit Prasad ◽  
Kamil Ara Khanom ◽  
...  
Keyword(s):  
Iron Deficiency ◽  
Total Dose ◽  
Iron Deficiency Anaemia ◽  
Intravenous Iron ◽  
Hemoglobin Level ◽  
Iron Sucrose ◽  
Iron Therapy ◽  
Deficiency Anaemia ◽  
Medical College ◽  
Intravenous Iron Therapy

Background: Iron deficiency anaemia is a common problem in antenatal patient especially in primigravida in developing world. The study was conducted to evaluate the efficacy of intravenous iron sucrose in antenatal primigravida anaemic cases. Aims and Objectives: The study was conducted to evaluate the response of intravenous iron therapy in anaemic antenatal primigravida patients. The rise of hemoglobin level was predicted after therapy. Materials and Methods: A prospective cross-sectional study was done in the antenatal clinic of Popular Medical College Hospital from January 2016 to December 2016. Primigravida women of e” 18 years with iron deficiency anaemia were included in this study. Pretreatment hemoglobin level was measured. After total dose of calculated iron, intravenous iron sucrose was infused to achieve the target hemoglobin. After completion of therapy hemoglobin was measured 2 weeks and 4 weeks after last dose of iron treatment. Mean, percentage, Chi-square test was done and P value <0.05 was considered significant. Results: Among the 63 primigravida anaemic patients mean age of the study subjects were 23.98 years with mean gestational age were 23.54 weeks. Their pretreatment hemoglobin level was 5.42 gm/dl. After total dose infusion of iron sucrose, the mean rise of hemoglobin after 2 weeks was 8.87 gm/dl and after 4 weeks was 10.87 gm/dl respectively. This findings were statistically significant (P<0.001). Attainment of target hemoglobin at the range of 9.1-11.0 gm/ dl was 50.79% and 65.08% after 2 weeks and 4 weeks respectively. Conclusion: Parenteral iron therapy in the form of iron sucrose proved to be better choice to correct iron deficiency anaemia in primigravida anaemic patients J Dhaka Medical College, Vol. 27, No.1, April, 2018, Page 79-82

scholarly journals A comparative study on efficacy and safety of intravenous iron sucrose and oral iron among anaemic pregnant females

2017 ◽  
Vol 6 (10) ◽  
pp. 4492
Author(s):  
Naheed Zia Khan ◽  
Mufazzal Ahmad ◽  
Akhilesh Dutt Dwivedi ◽  
Mukesh Shukla
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anaemia ◽  
Intravenous Iron ◽  
Oral Iron ◽  
Iron Sucrose ◽  
Deficiency Anaemia ◽  
Pregnant Females ◽  
Oral Group ◽  
The Mean ◽  
In Pregnancy

Background: Iron deficiency anaemia (IDA) is the most common medical problem in pregnancy. Both parenteral and oral iron therapies are modalities used for management of anaemia in pregnant females. The present study aimed to compare the efficacy of oral and intravenous iron therapy in improving iron deficiency anaemia in pregnancy and restoring iron stores, compare the pregnancy outcome in the two groups and evaluate their safety.Methods: This prospective randomized clinical trial conducted among pregnant women between 14 and 36 weeks with established IDA who were treated with IVIS (Intravenous Iron Sucrose) or OI (ferrous sulphate). All patients were monitored for laboratory response and adverse effects. Independent sample-t test, Chi square test and ANOVA were used for statistical analysis. P <0.05 was considered significant.Results: From first follow up till the end of the study the mean hemoglobin level of IV Group was found to be significantly higher as compared to that of oral Group. The MCV (mean corpuscular volume) values increased to a significant level in the intravenous group as compare to oral. After therapy increase transferrin saturation in the intravenous group were significantly higher at all-time interval than the oral group. The mean neonatal hemoglobin at birth was significantly higher in IV group 16.88±1.96 gm/dl than oral group 16.88±1.96 (p= p<0.0001).Conclusions: Intravenous iron sucrose is comparatively more efficient in improving haemoglobin than oral iron and has better pregnancy outcomes.

scholarly journals Intravenous versus oral iron therapy in treatment of postpartum anaemia

2017 ◽  
Vol 6 (8) ◽  
pp. 3454
Author(s):  
Neelima Agarwal ◽  
Preeti Sharma
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anaemia ◽  
Ferrous Sulphate ◽  
Intravenous Iron ◽  
Hemoglobin Level ◽  
Oral Iron ◽  
Chi Square ◽  
Deficiency Anaemia ◽  
Significant Difference ◽  
Red Cell Indices

Background: Postpartum iron deficiency anaemia (IDA) is common in women. Most women are treated with either oral iron supplementation or blood transfusion. Hence, the aim of our study was to compare the effect of treatment with either oral ferrous sulphate or intravenous ferrous sucrose on postpartum IDA.Methods: 100 postpartum women with proven iron deficiency anaemia with hemoglobin <9gm/dl and serum ferritin <15 µgm/l were included in the study. They were randomized to receive either oral ferrous sulphate 200 mg twice daily for 6 weeks (group 1) or intravenous ferrous sucrose 200 mg, two to three doses given on alternate days (group 2). Total iron deficit was calculated using a standard formula. Target hemoglobin was 11 gm/dl. Results were analysed by the students t-test and chi-square test. Hemoglobin, hematocrit, red cell indices and ferritin were measured on day 2-3, 1-2 weeks and 6 weeks postpartumResults: By 1-2 weeks, hemoglobin level in women treated with intravenous iron had risen from 7.81±0.849 to 9.88±0.760 gm/dl which was more than those treated with oral iron (p<0.01); although by 6 weeks, there was no significant difference between the two groups. Ferritin levels rose rapidly in those treated with intravenous iron and remained significantly higher than in those treated with oral iron (p<0.01).Conclusions: Intravenous iron sucrose increases the hemoglobin level more rapidly than oral ferrous sulphate in women with postpartum IDA. It also replenishes iron stores more rapidly. 

scholarly journals Anaemia in pregnancy: prevalence and treatment response to various modalities: a prospective study

2020 ◽  
Vol 9 (9) ◽  
pp. 3784
Author(s):  
G. D. Maiti ◽  
Shilpa Gupta ◽  
Jaskanwar Singh
Keyword(s):  
Iron Deficiency ◽  
Pregnant Women ◽  
Iron Deficiency Anaemia ◽  
Intravenous Iron ◽  
Iron Therapy ◽  
Deficiency Anaemia ◽  
Thalassemia Trait ◽  
Anaemia In Pregnancy ◽  
Intravenous Iron Therapy ◽  
In Pregnancy

Background: Anaemia seen in pregnancy are largely preventable and easily treatable if detected in time, despite this, anaemia still continues to be a common cause of maternal and perinatal morbidity and mortality in India.Methods: A prospective observational study of 200 pregnant women with anaemia was carried out from Jun 2017 to December 2018 at a Tertiary care hospital with pan India population. Patients underwent clinical examination and laboratory tests to find out the severity and type of anaemia and were treated accordingly. Iron deficiency anaemia was treated with oral or intravenous iron therapy depending upon the hemoglobin concentration. Patients were followed up after 28 days of treatment and hemoglobin estimation was done to monitor the treatment response.Results: A total 36.49% pregnant women had hemoglobin less than 10 gm%. 151 out of 200 women had serum ferritin <12 ng/ml which indicates that iron deficiency anaemia is the commonest type of anaemia in pregnancy. Overall, out of 200 patients 5.5% patients were found to have hemoglobinopathies (β thalassemia trait). After 28 days of treatment mean increase in hemoglobin was 2.40 gm% and 4.24 gm% in patients receiving oral and intravenous iron therapy respectively.Conclusions: A total 36.49% pregnant women were found to have anaemia during pregnancy and iron deficiency anaemia is the commonest type of anaemia. Therefore, there is still a need for dietary counselling and health education in the community. 5.5% patients were found to have beta thalassemia trait which was detected only after conducting hemoglobin electrophoresis. Both oral and intravenous iron therapy are effective in treatment of iron deficiency anaemia but intravenous iron therapy results in a more rapid resolution of anaemia.

Sign in / Sign up

Export Citation Format

Share Document